for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Oragenics Says Phase 2 Clinical Trial Of Ag013 Did Not Demonstrate Statistical Significance On Primary Endpoint

April 15 (Reuters) - Oragenics Inc:

* ORAGENICS, INC. ANNOUNCES EARLY TOP-LINE RESULTS OF PHASE 2 CLINICAL TRIAL OF AG013 FOR ORAL MUCOSITIS IN CHEMORADIATION TREATMENT OF HEAD AND NECK CANCER

* ORAGENICS INC - PHASE 2 CLINICAL TRIAL OF AG013 DID NOT DEMONSTRATE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up